FAST NEWS: Hutchmed Sells Cancer Drug’s Overseas Rights for up to $1.13 Billion
The latest: Hutchmed (China) Ltd. (HCM.US; 0013.HK) announced on Wednesday that it has exclusively licensed Japan’s Takeda Pharmaceutical (TAK.US; 4502.T) to develop, manufacture and sell its metastatic colorectal cancer drug…
